Rallybio Corp

RLYB

Company Profile

  • Business description

    Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.

  • Contact

    234 Church Street
    Suite 1020
    New HavenCT06510
    USA

    T: +1 203 859-3820

    https://www.rallybio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    24

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,772.001.00-0.01%
CAC 407,662.593.32-0.04%
DAX 4023,673.29236.32-0.99%
Dow JONES (US)44,575.47480.701.09%
FTSE 1008,785.3324.370.28%
HKSE24,072.28211.87-0.87%
NASDAQ20,240.17129.57-0.64%
Nikkei 22539,986.33501.06-1.24%
NZX 50 Index12,734.53131.711.05%
S&P 5006,206.321.370.02%
S&P/ASX 2008,541.101.20-0.01%
SSE Composite Index3,444.4320.200.59%

Market Movers